The document discusses immunotherapy strategies for multiple myeloma. It summarizes that while current therapies have improved survival, most patients still relapse. It then reviews several immunotherapeutic approaches including allogeneic stem cell transplantation, vaccination strategies targeting antigens like MAGE and idiotype, dendritic cell-based vaccines, and monoclonal antibodies targeting proteins like CS1, CD38, and CD138. Emerging cellular immunotherapies using chimeric antigen receptor (CAR) T cells and natural killer cells targeting myeloma antigens are also discussed. Clinical trials of these approaches demonstrate feasibility and some early signs of efficacy but also highlight ongoing challenges to further improve outcomes.
It is a neoplasm of B-cell lineage; proliferation of the cells forms a monoclonal population of plasma cells and produces a single type of Ig/Ig fragment.
It is a neoplasm of B-cell lineage; proliferation of the cells forms a monoclonal population of plasma cells and produces a single type of Ig/Ig fragment.
Allogeneic hematopoietic stem cell transplantation (allo HSCT) from an HLA-matched related donor provides the most potent anti-leukemic effect of any post-remission therapy in AML, as demonstrated by the lowest rates of relapse.
Graft vs leukemia plays and important role here.
Provides the best chance of long-term survival
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multi...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Shaji Kumar, MD, Professor of Hematological Malignancies
Mayo Clinic Cancer Center, offers expert insight on the assessment of MM, emerging and current therapies, cutting edge approaches to personalized treatments plans, and much more.
These hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.
Allogeneic hematopoietic stem cell transplantation (allo HSCT) from an HLA-matched related donor provides the most potent anti-leukemic effect of any post-remission therapy in AML, as demonstrated by the lowest rates of relapse.
Graft vs leukemia plays and important role here.
Provides the best chance of long-term survival
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multi...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Shaji Kumar, MD, Professor of Hematological Malignancies
Mayo Clinic Cancer Center, offers expert insight on the assessment of MM, emerging and current therapies, cutting edge approaches to personalized treatments plans, and much more.
These hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.
Implications for Immunotherapy of Acute Radiation Syndromes. Part 2.Dmitri Popov
Research Proposal: Implications for Immunotherapy of Acute Radiation Syndromes. Part 2.
Dmitri Popov
Full-text available · Research Proposal · Feb 2017
File name: Implications for Immunotherapy of ARS. Part 2.
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Will Roettger
This is a short briefing on the oncology immunotherapy PD-1/PD-L1 targeted agents currently under development. In this briefing we look at the competitive landscape, PD-1/PD-L1 product profiles, positioning, strategy, as well as a development timeline and SWOT on the BMS PD-1 blocker nivolumab. Updates to this briefing will come as newer information is discovered.
Ebmt 2018 gps in mm koehne et al_with suppl slides_final_final_1.1.12_mar2018...Nicholas Sarlis
Galinpepimut-S (WT1-targeting peptide vaccine) in high-risk multiple myeloma. Final results from a Phase 2 clinical study. Koehne G, et al. EBMT 2018 slide presentation.
Michael K. Wong, MD, PhD, provides an update on immunotherapy in melanoma at the 2017 MD Anderson Melanoma Patient Symposium held in Austin, TX on May 6, 2017.
Luciano J. Costa, MD, PhD, prepared useful Practice Aids pertaining to multiple myeloma for this CME activity titled "Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Dypn7b. CME credit will be available until March 12, 2020.
Justin F. Gainor, MD; Kurt Schalper, MD, PhD; and Edward B. Garon, MD, MS prepared useful Practice Aids pertaining to immunotherapy for this CME/MOC/CC/CNE activity titled, "New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations." For the full presentation, monograph, complete CME/MOC/CC/CNE information, and to apply for credit, please visit us at http://bit.ly/2UJuQBq. CME/MOC/CC/CNE credit will be available until April 25, 2020.
This presentation is part of MIU CE Pharmacy Program and is designed primarily for pharmacists with the following learning objectives:
1- Explain the mechanisms of action behind immune response to cancer and the application of immunotherapy in cancer treatment
2- Distinguish new and emerging immunotherapy classes and individual agents efficacy, safety to therapy in cancer treatment
3-Strategies to counsel and assist patients to overcome barriers to therapy, including Treatment side effects to improve adherence to therapy
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
1. Immunotherapy for Multiple
Myeloma
Nina Shah M.D.
Assistant Professor
Department of Stem Cell Transplantation
and Cellular Therapy
M.D. Anderson Cancer Center
2. Objectives
• Myeloma therapy: general principles
• Immunotherapy: general principles
• Allogeneic stem cell transplantation (SCT)
• Immunotherapies in development
3. Myeloma: We’ve come a long way
• Proteosome inhibitors
• Immunomodulatory agents
• Triple therapy
• High dose chemotherapy and autologous stem
cell transplantation
• Maintenance
6. Immunotherapy
• Allogeneic stem cell transplantation
• Vaccine strategies
• CAR T and NK cells
• Monoclonal antibodies
• NK cells
7. Immune system alterations in MM
• BM infiltration by plasma cells
• Interaction between MM cells and BM
microenvironment immunosuppression
• Decrease in number and functional activity of
immune cells
• Recruitment of immunosuppressive cells
• Deficient antigen processing/ presentation
• Expression of co-inhibitory molecules by tumor
cells
1. De Carvalho, Cancer Immunol Immunother 2013
2. Andrade, Cancer Immun, 2008
9. Allogeneic stem cell transplantation:
controversies remain
• Exploit the graft vs myeloma affect
• DLI’s have been used1
• Chronic GVH may predict for long term disease
control2,3 but this data has not been consistent
• Conflicting data in randomized studies comparing
tandem auto SCT vs auto- allo SCT4,5
• But true effect of allo SCT may take longer than 5
years to emerge
• Myeloablative (MA) allo SCT associated with 50%
TRM but some long term survivors (30-40%) 6
• Outcomes may be improved with better modern
supportive care measures 1. Tricot, Blood 1996
2. Crawley, Blood 2005
3. LeBlanc, BMT 2001
4. Krishnan, Lancet Oncol 2011
5. Bruno, NEJM 2007
6. Barlogie JCO 2006
11. MAGE
• MAGE-C1/CT7 and MAGE-C2/CT10: genes that
appear to be expressed in MM, solitary
plasmacytomas and MGUS1
• Function yet unknown
• MAGEC1/ CT7 gene frequently expressed in
advanced MM and is associated with worse
overall survival (OS) 2
• Resultant protein is immunogenic
• Thus potential cancer/testis antigen (CTA) /target
for immunotherapy
1. De Carvalho, Cancer Immunol Immunother 2013
2. Andrade, Cancer Immun, 2008
12. Clinical trial of MAGE-A3/Poly-ICLC immunizations
Followed by Adoptive Transfer of Vaccine-Primed and
Costimulated Autologous T Cells
• Phase 2 trial, 27 pts undergoing auto SCT for MM
• MAGE-A3 cancer-testis antigen (CTAg) vaccine
• Injected with TLR-3 agonist Poly-ICLC (Hiltonol)
adjuvant GM-CSF to enhance T-cell priming/ boosting
• Co-injection of Prevnar vaccine
• The protein also contains the HIV-1-TAT membrane
translocation sequence to facilitate formation of MHC
class I complexes
• Lenalidomide maintenance was started at day 100
1. Rapoport, Clin Cancer Res 2013
14. Results
• T-cell infusions were well tolerated
• Vaccine injection site reactions occurred in >90 pts
• 2/9 pts developed sterile abscesses
• MAGE-A3–specific CD8 T cells seen in 7 of 8 evaluable
HLA-A2 pts (88%)
• Vaccine-specific cytokine producing T cells generated in
19 of 25 patients (76%)
• Antibody responses developed in 7/9 patients (78%)
who received montanide and only weakly in 2/18
patients (11%) who did not
• 2-year OS was 74% and 2-year EFS was 56%
1. Rapoport, Clin Cancer Res 2013
16. Results
Limitation: MAGE-A3 expression in the myeloma cells was not required for
study entry; thus reducing ability to evaluate vaccine-specific T- and B-cell
responses
Double positive vaccine-directed IFN-gamma responses on CD4 and CD8 T
cells together was possibly associated with better EFS
1. Rapoport, Clin Cancer Res 2013
17. Idiotype Vaccine
• Targets the variable Ig on surface of plasma cell
• Idiotype-specific T cells at a low frequency have been
detected in 90% of patients with MM or MGUS1
• Induction of CTL activity against autologous myeloma
cells also shown after stimulation with idiotype-loaded
DCs
• Hypothesis that idiotype-specific response diminishes
MM progresses
• Thus far clinical trials have shown safety and some T
cell responses but no definitive clinical response.
1. Yi, Blood 1995
18. Dendritic cell-based vaccines
• DC’s from MM pts can present idiotype
determinants to autologous T cells1
• DC-tumor cell fusions
– Protection against MM in murine model2
• Vaccination with DC-fusion induces tumor immunity
and may work best in post-SCT setting when
minimal T regs
• Most efficient strategy may be vaccination with
lenalidomide on board as there may be decrease in
T cell PD-1 expression and inhibition of T regs
• Basis for upcoming BMT CTN 1401 trial
1. Dabadghao, Blr J Hematol 1998
2. Gong, Blood, 2002
22. Elotuzumab
• Humanized monoclonal antibody against CS1
• Phase 1b/2 trial with bortezomib: ORR of 48% and PFS
9.5 months
• Randomized phase 2, open label study in patients with
previously treated MM
• 2 doses evaluated: 10 mg/kg (n=36) and 20 mg/kg (n=
37) in combination with lenalidomide and low dose
dexamethasone.
• 10 mg/kg: PFS of 33 months, ORR of 92%
• 20 mg/kg: PFS of 18 months, ORR of 76%
• 10 mg/kg is being evaluated in the phase 3 studies
– ELOQUENT 1 (newly diagnosed MM patients)
– ELOQUENT 2 (relapsed MM patients)
1. Jakubowiak et al, in progress
2. Lonial, EHA June 2013
23. Relapsed/refractory myeloma
• Lonial et al, NEJM August 2015
• ELOQUENT-2: A phase III, randomized study of
lenalidomide (Len)/dexamethasone (dex)
with/without elotuzumab (Elo)
• PFS: ELd 19.4 (16.6, 22.2) months, Ld 14.9
(12.1, 17.2) months (HR [95% CI] 0.70 [0.57,
0.85]; p = 0.0004
• ORR (95% CI) was 79% (74, 83) ELd, 66% (60,
71) Ld (p = 0.0002)
24. CD38
• Cell adhesion molecule
• Regulates calcium flux and signal transduction
• On MM cells but also low level on CD4, CDD8,
sometimes BCs, NK cells
• But overall a good tumoe-specific candidate
26. • Phase Ib dose escalation trial (Martin et al, ASH
2014)
• SAR + len/dex
• N= 31, relapsed/ refractory MM
• No DLTs
• ORR 64.5%
• CBR 71%
• PFS 7.2 months
• Single agent activity with ORR of 24%
SAR 658094 Anti-CD38 MoAb
27. SAR 658094 Anti-CD38 MoAb
• SAR decreases MM cell adhesion to BM
accessory cells via blockage of CD31-CD38
interaction (An et al, ASH 2014)
• KIR3DL1, HLA-B Bw4-80Ile genotype predictive
of correlated with increased ORR and PFS
among patients treated with SAR/LEN/Dex
(Marra, ASH, 2014)
28. Daratumumab
• Combination with:
– VD or VTD (Newly dx)
– VMP (newly Dx and transplant inelligible)
– Pom/dex (relapsed/refractory)
• Well-tolerated
• Survival and response data pending (Lockhost,
ASH 2014)
• Given with len/dex in R/R MM:
– ORR = 75% (Plesner ASH 2014)
29. KIR
• Inhibitory receptor on NK cells
• Blocking this receptor is though to “activate”
autologous NK cells
• IPH2101 (Lirilumab)
30. IPH21011
• Phase I study
• N=32
• 7 dose levels
• Ex vivo enhancement of NK activity against
MM
• 1 SAE (AKI)
• No responses
1. Benson, Blood, 2102
34. Pre-Clinical data with CAR therapy for MM
• In vitro activity of CAR cells
– CD38-specific CAR T cells1
• In vivo activity of CAR-NK cells in murine models
– CS1-specific CAR-NK2
– CD138-specific CAR-NK3
• In vivo activity of CAR-T cells in murine models
– CS1-specific CAR-T cells4
– CD56-specific CAR-T cells5
– NKG2D-expressing CAR-T cells6
– NY-ESO-1-specific TCR- transduced T cells7
1. Mihara, Leukemia, 2012
2. Chu, Leukemia, 2013
3. Jiang, Mol Oncol, 2014
4. Chu, Clin Cancer Research, 2014
5. Benjamin, AACR, 2012
6. Barber, Genee Ther, 2011
7. Mastaglio, ASH 2014
35. CD138-targetting CAR NK Cells1
• CAR-scFv (4B3)-CD3ζ
• NK-92 cell line transduced
1. Jiang, Molec Oncology, 2014
40. Clinical trial of CD19 CAR-T cells
• Garfall et al, ASCO 2015
• Relapsed MM pts
• 1-5x107CTL019 cells infused 12-14 days after
high-dose melphalan + ASCT
• N=4
• hypogammaglobulinemia (4/4) and grade 1
cytokine release syndrome (1/4)
• Cells detectable in the 3 evaluable pts
• 2 CRs, 1 progression
41. NK cells: one paradigm for
adoptive cellular therapy
42. Why don’t autologous NK cells work?
• Altered balance of inhibitory and activating receptors
on autologous NK cells1
• Altered ligands on tumor cells - requiring more active
NK cells than at baseline2
• Change in distribution of NK cell subpopulations (LN,
PB) 3
• Direct immunosuppression by tumor cell –produced
soluble factors (cytokines, ligands) 1, 4
• NK cells from MM patients express PD-15
• Increased Class I on MM cells in advanced disease6
1. Lion, Leukemia, 2012
2. Veuillen, JCI, 2012
3. Gibson, Hum Pathol, 2011
4. Reiners, Blood, 2013
5. Benson, Blood, 2010
6. Carbone, Blood, 2005
43. Frozen cord
Blood unit
Ficoll
MNC
Culture condition:
2(γ-irradiated)APC : 1 cord TNC
IL-2 100u/ml
GP500 bioreactor
Day 7
CD3 depletion (CliniMACS)
CD3-depleted NK cells
Culture condition:
2(γ-irradiated)APC : 1 CD3 - cell
IL-2 100u/ml
For another 7 days
Day 14
CD3 depletion (CliniMACS)
CD3-depleted NK cells
CD3 + cells
CD3 + cells
Flow cytometry
on day7 & 14
CD56
CD16
CD3
CD19
CD14
CD45
Clinical NK Expansion Experimental Design
Thaw
Day 0
46. -8 -7 -5 0
Low dose lenalidomide
High dose
melphalan, 200
mg/m2
CB NK cells
Autologous
graft
Protocol 2011-0379: Phase I/II study of umbilical cord blood-
derived natural killer cells in conjunction with high dose
chemotherapy and autologous stem cell transplant for
patients with multiple myeloma
-2
1 x 108 cells/kg: no infusion reactions
or GVH thus far
47. Conclusions
• Though the timeline for patients with myeloma
has changed a definitive cure is still needed
• Myeloma is a malignancy of immune
dysregulation and likely immune exhaustion
• Therefore immunotherapies likely have an
important role in the treatment paradigm
• Fine tuning of antibody, cellular and vaccine
therapy will eventually lead us to the ideal
partners for the recently developed novel
therapies
Alimitation of this study was that MAGE-A3 expression in
the myeloma cells was not required for study entry, thus
reducing our ability to evaluate the clinical impact of
vaccine-specific T- and B-cell responses